Document Detail


Treatment of established prosthetic vascular graft infection with antibiotics preferentially concentrated in leukocytes.
MedLine Citation:
PMID:  3589979     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The efficacy of treating established vascular graft infections with rifampin and clindamycin (preferentially concentrated in leukocytes) and cefazolin (not concentrated in leukocytes) was studied in a canine model. Infrarenal aortic, 6 mm by 6 cm knitted Dacron double velour grafts were implanted and infected with 10(8) colony-forming units (CFU) of coagulase-positive Staphyloccus aureus organisms injected intravenously immediately after graft placement. Antibiotic therapy was instituted at 3 months postimplantation. Three groups were studied: (I) untreated controls (n = 3); (II) therapy with intravenous cefazolin 15 mg/kg/8 hr for 28 days (n = 7); and (III) combined therapy with intravenous rifampin 13 mg/kg/24 hr and intravenous clindamycin 13 mg/kg/8 hr for 28 days (n = 7). Grafts were removed for quantitative bacteriologic studies after the 28-day course of therapy. Two group I control grafts remained patent with 6.4 X 10(6) and 8.1 X 10(3) CFU S. aureus/gm of graft. The third control graft was thrombosed. Two group II animals demonstrated 1.6 X 10(7) and 2.3 X 10(5) CFU S. aureus organisms/gram of graft, respectively; the remaining five group II grafts were free of organisms. All group III grafts were sterile--a significant difference (p less than 0.05) from group I grafts. In this experimental model, established prosthetic graft infections were eradicated by intensive treatment with antibiotics preferentially concentrated in leukocytes.
Authors:
T W Wakefield; D R Schaberg; C L Pierson; J A Bouffard; N A Petry; K D Nolan; S A Spaulding; W M Whitehouse; J C Stanley
Related Documents :
1086909 - The probability of closure in aortocoronary vein bypass grafts.
1087109 - Vein graft patency and intimal proliferation after aortocoronary bypass: early and long...
8068879 - Probability of thrombosis of vascular access among hemodialysis patients treated with r...
23246119 - Comparative evaluation of topical versus intrastromal voriconazole as an adjunct to nat...
23331689 - Photodynamic therapy for pythiosis.
23561869 - Shoulder functionality after manual therapy in subjects with shoulder impingement syndr...
8869049 - Cost-effectiveness of carotid endarterectomy.
23682819 - The role of endoscopic third ventriculostomy in the treatment of hydrocephalus.
3579409 - Acute type a dissection of the aorta: surgical management with the sutureless intralumi...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Surgery     Volume:  102     ISSN:  0039-6060     ISO Abbreviation:  Surgery     Publication Date:  1987 Jul 
Date Detail:
Created Date:  1987-07-23     Completed Date:  1987-07-23     Revised Date:  2003-11-14    
Medline Journal Info:
Nlm Unique ID:  0417347     Medline TA:  Surgery     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  8-14     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Blood Vessel Prosthesis*
Cefazolin / metabolism,  therapeutic use
Clindamycin / metabolism,  therapeutic use*
Disease Models, Animal
Dogs
Drug Therapy, Combination
Female
Leukocytes / metabolism*
Rifampin / metabolism,  therapeutic use*
Staphylococcal Infections / drug therapy
Surgical Wound Infection / drug therapy*
Chemical
Reg. No./Substance:
13292-46-1/Rifampin; 18323-44-9/Clindamycin; 25953-19-9/Cefazolin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A simplified plan for follow-up of patients with colon and rectal cancer supported by prospective st...
Next Document:  Endoscopic insertion of endoprostheses in the treatment of postoperative cutaneous biliary fistula.